血管紧张素Ⅱ及其1型受体拮抗剂在卵巢癌中的作用机制  

Mechanism of AngiotensinⅡand Its Type 1 Receptor Blockers in Ovarian Cancer

作　　者：龚礼萍 孙立涛[1] 田家玮[1] GONG Li-ping;SUN Li-tao;TIAN Jia-wei(The Second Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第二医院,150001

出　　处：《国际妇产科学杂志》2022年第1期24-28,共5页Journal of International Obstetrics and Gynecology

摘　　要：卵巢癌是女性生殖系统常见的恶性肿瘤之一,由于其发病隐匿,大多数患者出现症状就诊时已属晚期,且易发生转移和复发,死亡率居妇科恶性肿瘤的首位。因此进一步探究卵巢癌发生发展机制、寻找肿瘤潜在治疗靶点至关重要。血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)是肾素-血管紧张素系统(renin-angiotensin system,RAS)中最具生物活性的因子,主要参与机体血压和水盐代谢的调节,目前研究发现其与血管紧张素1型受体(angiotensin type 1 receptor,AT1R)结合激活相关通路与卵巢癌的发生、发展及转移过程密切相关,而AT1R拮抗剂(angiotensin receptor blocker,ARB)可以与AT1R选择性结合阻断AngⅡ-AT1R通路,从而阻断或抑制AngⅡ在卵巢癌中的作用。深入研究血管紧张素Ⅱ及其1型受体拮抗剂在卵巢癌中的作用机制或许能为寻找卵巢癌新的治疗靶点提供依据。Ovarian cancer is one of the most common malignant tumors in the female reproductive system.Because of its insidious onset,most patients are already in advanced stage when they have symptoms,and are prone to metastasis and recurrence.The mortality rate of ovarian cancer ranks first among gynecological malignant tumors.Therefore,it is very important to further explore the mechanism of ovarian cancer and find potential therapeutic targets.AngiotensinⅡ(AngⅡ)is the most bioactive factor in renin-angiotensin system(RAS),mainly involved in the regulation of metabolism of the body′s blood pressure and salt water.At present,some studies found that it combined with the angiotensin type 1 receptor(AT1R)to activated related pathways and that is closely related to the process of the occurrence and development of ovarian cancer and metastasis.And AT1R antagonists angiotensin receptor blocker(ARB)can selectively bind to AT1R blocking AngⅡ-AT1R pathways,thereby blocking or inhibit AngⅡrole in ovarian cancer.Further study on the mechanism of AngⅡand its type 1 receptor antagonist in ovarian cancer may provide evidence for new therapeutic targets for ovarian cancer.

关 键 词：卵巢肿瘤 血管紧张素Ⅱ 受体 血管紧张素 1型 血管紧张素Ⅱ1型受体拮抗剂 

分 类 号：R737.31[医药卫生—肿瘤]